Guardant Health, Inc. (GH) KPIs and segments
Close on Nov 17, 2026Market cap $19.23BP/E –Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Guardant Health · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Guardant Health: 39 chỉ số vận hành, trong đó có Oncology Clinical Test Volume, Shield Colorectal Cancer Screening Test Volume và Biopharma Test Volume, lấy từ 590 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oncology($M) | 219 | 205 | 190 | 184 | 159 | 151 | 146 | 141 | 130 | 126 | |||
Biopharma and data($M) | 60.9 | 53.0 | 54.0 | 54.7 | 56.0 | 45.4 | 49.5 | 46.5 | 43.9 | 37.6 | |||
Screening($M) | 52.9 | 41.6 | 35.1 | 24.1 | 14.8 | 5.68 | 4.12 | 1.00 | 0 | 0 | |||
Licensing and other($M) | 2.06 | 2.14 | 2.18 | 1.95 | 2.57 | 1.86 | 2.57 | 2.73 | 3.03 | 5.16 | |||
United States($M) | 318 | 285 | 264 | 249 | 217 | 194 | 192 | 180 | 168 | 157 | 143 | ||
International($M) | 16.9 | 17.0 | 17.7 | 15.8 | 15.4 | 9.86 | 10.2 | 11.4 | 9.12 | 11.1 | 12.4 | ||
Oncology Clinical Test Volume1 | 117,000 | 104,000 | 86,000 | 79,000 | 74,000 | 64,000 | 59,000 | 57,300 | 53,100 | 49,400 | 46,900 | 46,400 | |
Oncology Clinical Test Volume Growth (YoY)(%) | 58.0% | 63.0% | 47.0% | 38.0% | 40.0% | 30.0% | 25.0% | 24.0% | 21.0% | 14.0% | 20.0% | 29.0% | |
Shield Colorectal Cancer Screening Test Volume1 | 83,000 | 66,000 | 44,000 | 38,000 | 24,000 | 16,000 | 9,000 | 6,400 | |||||
Shield Non-GAAP Cost per Test($) | 330 | 410 | 420 | 520 | |||||||||
Biopharma Test Volume (Legacy, Discontinued After Q4 2024)1 | 11,050 | 10,500 | 10,475 | 8,450 | 9,500 | ||||||||
Biopharma Test Volume Growth (YoY, Legacy Through Q4 2024)(%) | 16.0% | 40.0% | 56.0% | 37.0% | 16.0% | ||||||||
Total Revenue($M) | 361 | 335 | 302 | 281 | 265 | 232 | 204 | 202 | 192 | 177 | 169 | 155 | |
Out-of-Period Revenue (Prior-Period Performance Obligations)($M) | 8.40 | 14.3 | 22 | 7.90 | 16.8 | 8.90 | 12.2 | 3.40 | 18.2 | 15.2 | 15.8 | 2 | |
Total Deferred Revenue (Contract Liabilities)($M)2 | 45.1 | 52 | 56.7 | 59.7 | 56.4 | 60.7 | 44 | 41.6 | 32.5 | 35.4 | 27.8 | 22.9 | |
Current Deferred Revenue($M) | 38.1 | 44.8 | 47.8 | 50.8 | 46.9 | 54.4 | 36.3 | 35.5 | 29.6 | 29.4 | 22.6 | 18 | |
Long-Term Deferred Revenue($M) | 7 | 7.20 | 8.90 | 9 | 9.50 | 6.40 | 7.70 | 6.10 | 3 | 6 | 5.30 | 5 | |
Precision Oncology Testing Revenue (Legacy, Through Q4 2024)($M)1 | 185 | 181 | 167 | 156 | 142 | ||||||||
Development Services & Other Revenue (Legacy, Through Q4 2024)($M)1 | 17.2 | 10.9 | 10.7 | 12.3 | 12.9 | ||||||||
Non-GAAP Gross Profit($M)3 | 240 | 223 | 200 | 185 | 174 | 154 | 131 | 126 | 121 | 107 | 105 | 94.5 | |
Non-GAAP Gross Margin(%) | 67.0% | 67.0% | 66.0% | 66.0% | 66.0% | 66.0% | 65.0% | 63.0% | 63.0% | 60.0% | 63.0% | 61.0% | |
GAAP Gross Margin (Reported)(%) | 65.0% | 65.0% | 65.0% | 65.0% | 65.0% | 65.0% | 63.0% | 62.0% | 61.0% | 59.0% | 61.0% | 60.0% | |
Non-GAAP Cost of Revenue($M) | 121 | 112 | 102 | 95.8 | 90.9 | 78.3 | 72.2 | 75.4 | 70.4 | 70.4 | 63.2 | ||
Non-GAAP Operating Loss($M)3 | -47.2 | -65.2 | -68 | -74.6 | -54.5 | -61.5 | -68.3 | -88.3 | -66.3 | -71.9 | -71.2 | -88.5 | |
Non-GAAP Research & Development Expense($M) | 84.9 | 80.5 | 76.6 | 85.9 | 75.8 | 72.5 | 74.9 | 81.1 | 68.4 | 73 | 73.4 | 80 | |
Non-GAAP Sales & Marketing Expense($M) | 159 | 172 | 154 | 131 | 116 | 108 | 94.1 | 95.8 | 84.6 | 74.6 | 73.1 | 72.7 | |
Non-GAAP General & Administrative Expense($M) | 43.4 | 35.4 | 37 | 43.5 | 37.1 | 34.9 | 30.6 | 37.8 | 34.4 | 31.2 | 30 | 30.4 | |
Adjusted EBITDA($M)1 | -37.3 | -55.9 | -58.9 | -64.9 | -45.5 | -51.9 | -58.5 | -78.4 | -56.2 | -61.9 | -61.1 | -78.4 | |
Stock-Based Compensation & Payroll Tax Adjustment($M) | -3.90 | -3.90 | -3.20 | -3.50 | -2.60 | -2.80 | -2.40 | -2 | -3.90 | -1.80 | -1.80 | -1.20 | |
Non-GAAP Net Loss($M)1 | -38.8 | -56.2 | -58.7 | -63.8 | -48.3 | -55 | -61.1 | -77.3 | -55 | -58.5 | -56.4 | -75.9 | |
Non-GAAP Diluted Net Loss per Share($) | -0.29 | -0.42 | -0.45 | -0.50 | -0.39 | -0.44 | -0.49 | -0.62 | -0.45 | -0.48 | -0.46 | -0.64 | |
Company-Reported Free Cash Flow($M) | -37.2 | -69.5 | -71.2 | -54.2 | -45.8 | -65.9 | -67.1 | -83.4 | -55.3 | -99.1 | -37.2 | -82.8 | |
Full-Year Total Revenue Guidance — Low End($M)11 | 1,360 | 1,340 | 1,300 | 1,250 | 965 | 915 | 880 | 850 | 720 | 655 | |||
Property & Equipment, Gross($M)7 | 376 | 370 | 355 | 345 | 316 | 311 | 305 | 302 | 282 | 279 | 276 | 272 | |
Laboratory Machinery & Sequencing Equipment (Gross)($M) | 165 | 159 | 154 | 144 | 139 | 136 | 132 | 125 | 125 | 124 | 120 | 118 | |
Laboratory & Facility Leasehold Improvements (Gross)($M) | 119 | 112 | 111 | 108 | 105 | 105 | 104 | 104 | 103 | 103 | 103 | 102 | |
Computer Hardware & Bioinformatics Infrastructure (Gross)($M) | 50.3 | 50.3 | 43.5 | 41.3 | 40.5 | 38.9 | 37 | 36.5 | 36.1 | 35.2 | 34.8 | 34.4 | |
Construction in Progress (Gross)($M) | 30.7 | 38.3 | 36.1 | 41.3 | 21.4 | 20.9 | 22.3 | 28.1 | 7.20 | 7.40 | 8.40 | 7.50 | |
Furniture & Fixtures (Gross)($M) | 8.50 | 8.50 | 8.50 | 8.50 | 8.50 | 8.40 | 7.90 | 7.90 | 8 | 7.90 | 8 | 8 | |
Capitalized Computer Software (Gross)($M) | 2 | 2 | 2 | 2 | 2 | 1.70 | 1.70 | 1.70 | 2.10 | 2 | 2 | 2.10 | |
Accumulated Depreciation($M) | -224 | -214 | -205 | -199 | -191 | -185 | -175 | -166 | -157 | -147 | -137 | -127 | |
Total Undiscounted Operating Lease Payments($M)2 | 214 | 221 | 231 | 238 | 246 | 255 | 215 | 220 | 226 | 229 | 238 | 247 | |
Weighted-Average Remaining Operating Lease Term(năm) | 6.0 | 6.2 | 6.4 | 6.7 | 6.9 | 7.1 | 7.2 | 7.5 | 7.7 | 7.9 | 8.1 | 8.3 | |
Weighted-Average Operating Lease Discount Rate(%) | 4.5% | 4.5% | 4.5% | 4.5% | 4.5% | 4.5% | 3.8% | 3.8% | 3.8% | 3.8% | 3.8% | 3.9% | |
U.S. Share of Long-Lived & Right-of-Use Assets(%) | 99.0% | 99.0% | 99.0% | 100.0% | 100.0% | 100.0% | 99.0% | 99.0% | 99.0% | 99.0% | 99.0% | 98.0% | |
Cumulative FDA PMA & Supplement Approvals (Guardant Assays)1 | 50 | 41 | 35 | 33 | 30 | 27 | 26 | 22 | 21 | 19 | 17 | 14 | |
New FDA PMA & Supplement Approvals in Period | 9 | 6 | 2 | 3 | 3 | 1 | 4 | 1 | 2 | 2 | 3 | 0 | |
Cumulative Registered Clinical Studies Involving Guardant Assays1 | 40 | 38 | 36 | 36 | 36 | 35 | 34 | 34 | 34 | 33 | 33 | 33 | |
Newly Started Clinical Studies Involving Guardant Assays | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 2 | |
Natera, Inc. (NTRA) — Revenue($M)1 | 794 | 753 | 697 | 665 | 592 | 547 | 502 | 476 | 440 | 413 | 368 | 311 | |
Myriad Genetics, Inc. (MYGN) — Revenue($M)1 | 203 | 191 | 200 | 210 | 206 | 213 | 196 | 211 | 213 | 212 | 202 | 197 | |
Veracyte, Inc. (VCYT) — Revenue($M)1 | 152 | 150 | 139 | 141 | 132 | 130 | 114 | 119 | 116 | 114 | 97 | 98 | |
CareDx, Inc. (CDNA) — Revenue($M)1 | 139 | 132 | 118 | 108 | 100 | 87 | 85 | 87 | 83 | 92 | 72 | 66 | |
Illumina, Inc. (ILMN) — Revenue($M)1 | 1,129 | 1,159 | 1,091 | 1,159 | 1,084 | 1,059 | 1,041 | 1,104 | 1,080 | 1,112 | 1,076 | 1,119 | |
Quest Diagnostics Inc. (DGX) — Revenue($M)1 | 3,097 | 3,043 | 2,895 | 2,806 | 2,816 | 2,761 | 2,652 | 2,621 | 2,488 | 2,397 | 2,366 | 2,288 | |
Labcorp Holdings Inc. (LH) — Revenue($M)1 | 3,810 | 3,731 | 3,538 | 3,516 | 3,564 | 3,527 | 3,345 | 3,329 | 3,282 | 3,221 | 3,177 | 3,033 | |
U.S. Personal Consumption Expenditures: Health Care Services (SAAR)($M)1 | 3,858,700 | 3,790,300 | 3,699,900 | 3,667,000 | 3,614,900 | 3,529,800 | 3,464,700 | 3,417,800 | 3,358,200 | 3,288,200 | 3,244,400 | 3,159,400 | |
Exact Sciences Corp. (EXAS, Standalone Through Q4 2025) — Revenue($M)1 | 878 | 851 | 811 | 707 | 713 | 709 | 699 | 638 | 647 | ||||
GAAP Gross Profit8 | |||||||||||||
Total Assets($M)11 | 1,886 | 1,912 | 1,915 | 2,014 | 1,277 | 1,332 | 1,344 | 1,486 | 1,539 | 1,609 | 1,705 | 1,786 | |
Operating Cash Flow (GAAP)($M)3 | -23.7 | -57.8 | -65.6 | -26.4 | -35.4 | -60.3 | -62.7 | -64.5 | -51.1 | -94 | -30.3 | -78.7 | |
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Reporting framework transition (Q1 2025): Beginning Q1 2025, Guardant Health replaced its historical two-line revenue presentation (Precision Oncology Testing and Development Services & Other) with four disaggregated product lines (Oncology, Biopharma & Data, Screening, and Licensing & Other). Oncology Clinical Test Volume (excluding Shield) forms a continuous series across both eras, while discontinued Biopharma Test Volume and legacy two-line revenue/cost series are preserved on separate legacy rows through Q4 2024.
- Quarterly period-splitting derivations: Only cumulative year-to-date GAAP cash flow items (Q2 = 6M − Q1, Q3 = 9M − 6M, Q4 = FY − 9M) and Q4 out-of-period performance obligation revenue / disaggregated footnote lines (Q4 = full year Form 10-K minus nine months Q3 Form 10-Q) are derived by period subtraction; no ratios, sums, or margins are computed.
- Point-in-time year-end balances: December 31 balance sheet, gross PP&E, deferred revenue, and operating lease figures in Form 10-K / Q4 releases represent both fiscal year-end (FY) and fourth-quarter-end (Q4) balances.
- Shield colorectal cancer screening: Received FDA Premarket Approval in July 2024, launched commercially in Q4 2024 (6,400 tests), and received CMS Advanced Diagnostic Laboratory Test (ADLT) status at a $1,495 Medicare rate effective April 1, 2025.
Không hiện vì thiếu các kỳ gần đây (7)
- Product-level ASP ranges (Guardant360 Liquid $3,000–$3,100; Guardant360 Tissue ~$2,000; Guardant Reveal $600–$700; Shield ~$800–$880) — disclosed only intermittently on earnings calls or as ranges rather than continuous exact quarterly series.
- Implied average revenue per test (Revenue divided by Test Volume) — omitted because blended Oncology revenue includes out-of-period cash collection upsides and Guardant does not publish an audited per-test ASP table.
- Remaining Performance Obligations (RPO) — Guardant applies the ASC 606-10-50-14 practical expedient for contracts with original expected durations of one year or less and variable consideration; long-term RPO was not continuously disclosed through FY2025.
- Ordering oncologists, biopharma partner count, patient biobank samples (>1,000,000), Shield covered lives (>80% commercial / ~100 million total in Q3 2026), and total patent portfolio (800+ patents and applications) — communicated primarily as milestone lower bounds ('more than', 'over', '+') rather than exact continuous period-end counts.
- Medicare share of precision oncology clinical revenue (45% in FY2022, 43% in FY2023, 39% in FY2024) — no longer disclosed on a comparable basis in the FY2025 Form 10-K following the Q1 2025 revenue disaggregation change.
- Scope 3 indirect value-chain GHG emissions (54,270 mtCO2e in FY2023; 51,463 mtCO2e in FY2024) — omitted because FY2025 Scope 3 calculations remained in progress as of the May 2026 Corporate Responsibility Report Update.
- Subsidiary standalone operational breakdowns (Guardant Health AMEA, Guardant Health Japan Corp.) — wholly owned subsidiaries are fully consolidated under U.S. GAAP without separate standalone public filings.
Dữ liệu cập nhật 2026-11-07.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Diagnostic Test Volumes & Unit Economics
Product Line Revenue, Reimbursement Adjustments & Contract Liabilities
Non-GAAP Operating Performance & Quarterly Full-Year Guidance
CLIA Laboratory Infrastructure, Gross PP&E & Lease Commitments
Workforce, Environmental Footprint, Product Safety & Governance
FDA Regulatory Approvals, Clinical Trials & Diagnostics Industry Benchmarks
- Cumulative FDA PMA & Supplement Approvals (Guardant Assays)25 kỳ
- Cumulative Registered Clinical Studies Involving Guardant Assays44 kỳ
- Natera, Inc. (NTRA) — Revenue ($M)43 kỳ
- Myriad Genetics, Inc. (MYGN) — Revenue ($M)42 kỳ
- Veracyte, Inc. (VCYT) — Revenue ($M)43 kỳ
- CareDx, Inc. (CDNA) — Revenue ($M)43 kỳ
- Illumina, Inc. (ILMN) — Revenue ($M)38 kỳ
- Quest Diagnostics Inc. (DGX) — Revenue ($M)43 kỳ
- Labcorp Holdings Inc. (LH) — Revenue ($M)43 kỳ
- U.S. Producer Price Index: Medical & Diagnostic Laboratories (Index)129 kỳ
- U.S. Personal Consumption Expenditures: Health Care Services (SAAR) ($M)43 kỳ
- Exact Sciences Corp. (EXAS, Standalone Through Q4 2025) — Revenue ($M)36 kỳ
Geographic Revenue & Financial Statement Context
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Guardant Health
- Guardant Health Form 10-Q (filed 2026-11-05) ↗
- Guardant Health Form 8-K Earnings Release (filed 2026-11-05) ↗
- Guardant Health Form 10-K (filed 2026-02-19) ↗
- Guardant Health Form 8-K Earnings Release (filed 2026-02-19) ↗
- Guardant Health Form 8-K Earnings Release (filed 2025-02-20) ↗
- Guardant Health 2026 Corporate Responsibility Report Update (May 2026) ↗
- U.S. FDA Premarket Approval (PMA) Database — Guardant Health ↗
- ClinicalTrials.gov — Registered Studies Involving Guardant Assays ↗
- Exact Sciences Corp. SEC 10-K (XBRL) ↗
- Guardant Health Schedule 14A Proxy (filed 2026-04-28) ↗
- Natera, Inc. SEC 10-Q (XBRL) ↗
- Natera, Inc. SEC 10-K (XBRL) ↗
See a number that looks wrong?